Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1645 1646 1647 1657 1674 1678
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17920118 | PAN-ELR+ CXC CHEMOKINE ANTIBODIES FOR THE TREATMENT OF RESPIRATORY DISEASE | Non-Final OA | Eli Lilly and Company |
| 17428995 | TREATMENT OF PATIENTS AT RISK OF RAPID PROGRESSION OF OSTEOARTHRITIS WITH AN FGF-18 COMPOUND | Non-Final OA | MERCK PATENT GMBH |
| 18013462 | GLP-1R AGONIST / FGF21 FUSION PROTEINS | Non-Final OA | SANOFI |
| 18301187 | NON-COVALENT PROTEIN-HYALURONAN CONJUGATES FOR LONG-ACTING OCULAR DELIVERY | Non-Final OA | HOFFMANN-LA ROCHE INC. |
| 18255609 | POLYPEPTIDES FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION | Non-Final OA | Wisconsin Alumni Research Foundation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy